Nesta urges wider access to weight-loss drugs based on medical need

• Nesta urged broader access to GLP-1 weight-loss medicines based on clinical need rather than ability to pay, responding to a parliamentary report.
• NHS England plans to prioritize around 220,000 people during the rollout's first three years.
• The rollout could take up to 12 years, while 3,400,000 people meet NICE eligibility criteria.
• Director of healthy life Charley Lintern called for streamlined obesity care, including support to sustain weight loss once medication ends.
• Lintern urged the government to implement the healthy food standard, including targets for large food businesses to sell healthier food.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nesta Investment Management LLP published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.